Qilu Pharmaceutical Co., Ltd.
Clinical trials sponsored by Qilu Pharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Cheaper cancer drug on the horizon? new biosimilar QL2109 tested in healthy men Results expected Sep 2026 (estimated)
- New drug combo shows promise for Hard-to-Treat cancers Results expected Oct 2026 (estimated)
- New hope for bile duct cancer: experimental drug combo enters Mid-Stage trial Results expected Oct 2026 (estimated)
- New pill QLS-1304 enters human testing for advanced cancers Results expected Nov 2026 (estimated)
- New daily pill could ease heavy periods from fibroids Results expected Nov 2026 (estimated)
-
New pill aims to tame stubborn high blood pressure
Disease control By invitation onlyThis study tests a new daily pill called QLS1410 in 260 adults whose high blood pressure remains high despite taking two or more medications. Participants will receive either QLS1410 or a placebo for 12 weeks. The main goal is to see if QLS1410 can lower systolic blood pressure m…
Phase 2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for lung cancer patients with no PD-L1 marker
Disease control OngoingThis study tests whether a new drug called QL1706, combined with chemotherapy, works better than another drug (tislelizumab) plus chemo for people with advanced non-small cell lung cancer that lacks the PD-L1 protein. About 606 adults aged 18-75 are taking part. The goal is to se…
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New fertility drug QL1012D put to the test against Gonal-F®
Knowledge-focused OngoingThis study tests a new injectable fertility drug (QL1012D) against an approved one (Gonal-F®) in 48 healthy women aged 18-45. The goal is to see if the new drug works the same way in the body and is just as safe. Participants receive both drugs at different times to compare them …
Phase 1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC